@article{976278b438d94323a8873836705dc159,
title = "Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy",
abstract = "The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.",
author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, {Steven E.} and Saeed Dabestani and Rachel Giles and Fabian Hofmann and Milan Hora and Kuczyk, {Markus A.} and Thomas Lam and Lorenzo Marconi and Merseburger, {Axel S.} and Alessandro Volpe and Axel Bex",
note = "Funding Information: Thomas Powles is a company consultant for and has received grant or research support from Novartis, Pfizer, and GSK; has received speaker honoraria from Novartis, Pfizer, GSK, and Genentech; and has participated in trials for GSK, Pfizer, BMS, Genentech, and Genetech. Axel Bex has received speaker honorarium from Pfizer; has participated in trials for Pfizer Europe; has participated on advisory boards for GSK and Novartis; is a company consultant for Pfizer and Novartis; and has received grant or research support from Pfizer. Michael Staehler is a company consultant for Pfizer, Novartis, GSK, Roche, Astellas, and Bayer; has received speaker honoraria from Pfizer, Novartis, GSK, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GSK, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowship and travel grants from Pfizer, Novartis, GSK, Roche, and Bayer; and has received grant or research support from Pfizer, Novartis, GSK, Roche, Aveo, and Bayer. B{\"o}rje Ljungberg has received speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has participated on advisory boards for Pfizer and GSK. Karim Bensalah has received grant or research support from Pfizer and has received honoraria or consulting fees from Intuitive Surgical. Steven E. Canfield has received speaker honoraria from Amgen, Genomic Health Company, Algeta, and Bayer. Milan Hora has received speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grant or research support from Ipsen. Markus A. Kuczyk holds stock in Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal AG; has received speaker honoraria from Pfizer, Astellas, Bayer, GSK, Pierre Fabre, and Jansen Cilag & Hexal; has participated in the Protect Study, Millenium Study C21004, and Millenium Study C21005 and has participated in trials for Astellas, Ipsen, and Janssen; and has received grant or research support from Wyeth and Pfizer. Thomas Lam is a company consultant for Pfizer, GSK, Astellas, and Ipsen and has received speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grant or research support from Wyeth; has participated in a company-sponsored speaker's bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Saeed Dabestani, Rachel Giles, Fabian Hofmann, Lorenzo Marconi, and Alessandro Volpe have nothing to disclose.",
year = "2016",
month = jan,
day = "1",
doi = "10.1016/j.eururo.2015.10.017",
language = "English",
volume = "69",
pages = "4--6",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "1",
}
